Table 3.
Various miRNAs-based therapeutic strategies investigated in PCa.
| Therapeutic Strategy | MiRNA | Setting | Delivery route | Delivery vector | Effect | ||
|---|---|---|---|---|---|---|---|
| MiRNA Inhibition | AMOs | Antagomir | miR-221/222 | In-vivo | Intratumoral injection | - | Restoring p27/ Inhibiting PC3 tumor cells proliferation [97] |
| LNA | MiR-21 | Ex-vivo |
|
- | Restoring PTEN/ Inducing DU145 tumor cells apoptosis [205] | ||
| PNA | MiR-21 | In-vivo | Intravenous injection | - | Restoring PTEN/ Inducing DU145 tumor cells apoptosis [205] | ||
| - | miR-141/ miR-375 | In-vivo | Intraperitoneal | PEI nanoparticles | Reducing PC3-derived tumor growth [206] | ||
| - | miR-150/ miR-638 | In-vivo | Intraperitoneal | PEI nanoparticles | Suppressing MDM4/ Reducing melanoma tumor growth and inhibition of metastasis [206] | ||
| miRNA sponge | miRNA-767-5p | Ex-vivo | - | - | Restoring TET1/ Inhibiting human enzalutamide resistant prostate cells proliferation and invasion [207] | ||
| MiRNA replacement | miRNA mimics | MiR-185 | Ex-vivo | - | - | Inhibiting AR and repressing CDC6/ Inhibiting migration, invasion, and tumor formation ability of LNCaP cells [208] | |
| MiR-34a | In-vivo | Tail vein | Chitosan nanoparticles | Suppressing MET and Axl/ Deceasing growth of PC3-derived bone-metastatic PCa and inducing autophagy [209] | |||
| MiR-145 | In-vivo | Intravenous injection | Polyarginine-conjugated PEI | Decreasing PC3 peritoneal prostate tumor growth and increasing survival time [210] | |||
| MiR-15a and MiR-16-1 | In-vivo | Intravenous injection | Aptamer-conjugated ATE | Decreased growth and increased survival time in human PCa bone metastasis mice model [211] | |||
| MiR-145 | In-vivo | Intravenous injection | Mimic conjugated with polyarginine | Radiosensitizing PC3 and LNCaP tumors [212] | |||
Abbreviations: miRNA; microRNA, miR; microRNA, AMOs; anti-miRNA oligonucleotides, LNA; Locked nucleic acid, PNA; peptide nucleic acid, PEI; polymer nanoparticle polyethyleneimine, ATE; Atelocollagen, PTEN; Phosphatase and TENsin homolog, MDM4; MDM4 Regulator of P53, TET1; Tet methylcytosine dioxygenase 1, AR; androgen receptor, CDC6; Cell Division Cycle 6, MET; mesenchymal to epithelial transition, Axl; AXL Receptor Tyrosine Kinase, PCa; prostate cancer.